Glaukos Co. (NYSE:GKOS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its stake in shares of Glaukos Co. (NYSE:GKOS) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 381,288 shares of the medical instruments supplier’s stock after selling 11,822 shares during the period. New York State Common Retirement Fund’s holdings in Glaukos were worth $57,170,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. WCM Investment Management LLC boosted its holdings in shares of Glaukos by 45.7% during the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier’s stock worth $12,721,000 after purchasing an additional 31,084 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Glaukos by 186.9% in the third quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after acquiring an additional 8,942 shares during the last quarter. First Turn Management LLC acquired a new position in Glaukos in the third quarter valued at approximately $12,520,000. Harbor Capital Advisors Inc. acquired a new position in Glaukos in the fourth quarter valued at approximately $3,679,000. Finally, Victory Capital Management Inc. lifted its holdings in Glaukos by 421.8% in the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock valued at $10,320,000 after acquiring an additional 64,031 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on GKOS. Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Monday, December 2nd. Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. BTIG Research boosted their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, UBS Group initiated coverage on Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $159.42.

Glaukos Stock Up 5.5 %

Glaukos stock opened at $161.30 on Thursday. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71. The stock’s fifty day simple moving average is $152.65 and its 200-day simple moving average is $139.03. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $8.89 billion, a P/E ratio of -53.41 and a beta of 1.04.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,859,454.08. This represents a 23.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is currently owned by company insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.